Drug intelligence / Profile preview

donor-derived ex-vivo expanded natural killer cell (Pediatric Transplant and Cellular Therapy Consortium)

Development stage: Unknown
Lead developer: Children's Hospital Los Angeles
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Donor-derived ex-vivo expanded natural killer (NK) cells are an adoptive cellular immunotherapy product. These cells are isolated from a healthy donor, typically a human leukocyte antigen (HLA)-haploidentical relative, and expanded ex-vivo using cytokines (such as IL-2 or IL-15) to reach a high therapeutic dose. In the context of the EXCEL study (NCT04347616), these cells are administered to pediatric and young adult patients with high-risk acute myeloid leukemia (AML) who are undergoing haploidentical hematopoietic cell transplantation (haploHCT). The therapeutic goal is to enhance immune reconstitution and provide a graft-versus-leukemia (GVL) effect. NK cells are particularly effective in the haploidentical setting due to KIR-ligand mismatch, which triggers NK cell activation against residual leukemia cells without significantly increasing the risk of graft-versus-host disease (GVHD).

Other names: haploidentical natural killer cellsex-vivo expanded HLA-haploidentical donor natural killer cellsDonor-Derived Ex-Vivo Expanded Natural Killer Cell

Beyond the preview

Go deeper on donor-derived ex-vivo expanded natural killer cell (Pediatric Transplant and Cellular Therapy Consortium).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donor-derived ex-vivo expanded natural killer cell (Pediatric Transplant and Cellular Therapy Consortium).

Explore the full profile